1265PPhase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. (23rd October 2018) - Ribas, A; Mehmi, I; Medina, T; Lao, C; Kummar, S; Amin, A; Deva, S; Salama, A K; Tueting, T; Milhem, M; Hoimes, C J; Daniels, G; et al.